Bridgewater, NJ, United States of America

Anandan Palani

USPTO Granted Patents = 70 (Patent Applications = 34)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 21 (Patent Applications = 37)

Average Co-Inventor Count = 8.4

ph-index = 9

Forward Citations = 336(Granted Patents)

DiyaCoin

= 0.20

Inventors with similar research interests:

Location History:

Kenilworth, NJ (US) (2002 - 2008)
Bridgewater, NJ (US) (2005 - 2022)
Needham, MA (US) (2022 - 2023)

Company Filing History:

35 out of 2,405

Merck Sharp + Dohme Corp.

Schering-plough Corporation

patents

6. 4 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2025

where 'Filed Patents' based on already Granted Patents

70 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12297208 - Small molecule inhibitors of KRAS G12C mutant (2025-05-13),

2. 12291538 - Small molecule inhibitors of KRAS G12C mutant (2025-05-06),

3. 12240867 - Arginase inhibitors and methods of use (2025-03-04),

4. 12215116 - Arginase inhibitors and methods of use (2025-02-04),

5. 11697657 - Small molecule inhibitors of KRAS G12C mutant (2023-07-11),

6. 11566057 - Long-acting co-agonists of the glucagon and GLP-1 receptors (2023-01-31),

7. 11492385 - Long-acting co-agonists of the glucagon and GLP-1 receptors (2022-11-08),

8. 11274111 - Arginase inhibitors and methods of use (2022-03-15),

9. 11058775 - Insulin dimer-incretin conjugates (2021-07-13),

10. 10793615 - Long-acting co-agonists of the glucagon and GLP-1 receptors (2020-10-06),

11. 10493125 - Co-agonists of the glucagon and GLP-1 receptors (2019-12-03),

12. 10413593 - Co-agonists of the glucagon and GLP-1 receptors (2019-09-17),

13. 9969711 - [object Object] (2018-05-15),

14. 9745324 - Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use (2017-08-29),

15. 9688693 - [object Object] (2017-06-27),

Title: Unveiling the Inventive Genius of Anandan Palani

Introduction:

Anandan Palani, a prolific inventor based in Bridgewater, NJ (US), has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 66 patents. His innovative work focuses on developing novel therapeutic agents, with a recent emphasis on small molecule inhibitors of the KRAS G12C mutant and long-acting co-agonists of the glucagon and GLP-1 receptors.

Latest Patents:

Among his latest patents, Anandan Palani has introduced groundbreaking compounds of Formula (I) that can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein. These compounds hold promise as potent therapeutic agents for the treatment of cancer. Additionally, his work encompasses the development of long-acting co-agonists targeting the glucagon and GLP-1 receptors, offering potential advancements in managing metabolic disorders.

Career Highlights:

Anandan Palani has held pivotal roles at prestigious pharmaceutical companies, including Merck Sharp & Dohme Corporation and Schering Corporation. His expertise and innovative approach have been instrumental in driving forward pharmaceutical research and development efforts, ultimately leading to the creation of impactful therapies.

Collaborations:

Throughout his career, Anandan Palani has collaborated closely with esteemed colleagues such as Dong Xiao and Xianhai Huang. These collaborations have fostered a dynamic environment for innovation, enabling the exchange of ideas and expertise to propel groundbreaking research initiatives forward.

Conclusion:

In conclusion, Anandan Palani emerges as a visionary inventor whose relentless pursuit of scientific excellence has yielded a remarkable patent portfolio. His pioneering work in the realm of pharmaceuticals underscores his commitment to advancing healthcare through innovative solutions. Anandan Palani's contributions continue to shape the landscape of modern medicine, offering hope and healing to those in need.

This text is generated by artificial intelligence and may not be accurate.